share_log

NexImmune | DEFA14A: Others

SEC ·  Jan 18 00:00

Summary by Moomoo AI

NexImmune, Inc. has announced the adjournment of its Special Meeting of Stockholders originally scheduled for January 18, 2024, to a new date of February 7, 2024. The meeting, which will be held virtually via live webcast, is set to discuss the approval of the company's liquidation and dissolution as well as the Plan of Liquidation and Dissolution. Stockholders as of the record date, November 6, 2023, are entitled to vote at the rescheduled meeting. The company has provided various methods for stockholders to submit their proxy votes, including over the Internet, by telephone, by mail, or directly at the Special Meeting. Voting will remain open until 11:59 p.m. Eastern Time on February 6, 2024, for Internet and telephone submissions, while mailed proxies must be received by the same date. NexImmune has engaged Laurel Hill Advisory Group, LLC as its proxy solicitor to assist stockholders with the voting process and any related inquiries.
NexImmune, Inc. has announced the adjournment of its Special Meeting of Stockholders originally scheduled for January 18, 2024, to a new date of February 7, 2024. The meeting, which will be held virtually via live webcast, is set to discuss the approval of the company's liquidation and dissolution as well as the Plan of Liquidation and Dissolution. Stockholders as of the record date, November 6, 2023, are entitled to vote at the rescheduled meeting. The company has provided various methods for stockholders to submit their proxy votes, including over the Internet, by telephone, by mail, or directly at the Special Meeting. Voting will remain open until 11:59 p.m. Eastern Time on February 6, 2024, for Internet and telephone submissions, while mailed proxies must be received by the same date. NexImmune has engaged Laurel Hill Advisory Group, LLC as its proxy solicitor to assist stockholders with the voting process and any related inquiries.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more